DRUG REGULATORY AUTHORITY OF PAKISTAN
Division of Quality Assurance and Laboratory Testing

RAPID ALERT

DRAP ALERT No: Nº I/S/10-30-48

Spurious/Falsified Influvac Tetra Vaccine (BATCH # P13)

Date: 30th October, 2026

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Consumers

Problem Statement:

Provincial Inspector of Drugs, Lahore has registered a case regarding the alleged supply of Spurious/Falsified Influvac Vaccine. Verification from the authorized supplier confirmed that Batch No. P13 was Spurious/Falsified and not part of the legitimate supply chain.

The detection and recovery of a spurious Influvac Tetra Vaccine (Batch No. P13) being marketed and supplied through online channels presents a **significant public health risk**, as administration of a falsified vaccine may fail to provide the intended immunological protection and could expose recipients to unknown safety risks. Following are the details:

Sr. No.	Name of product	Batch Number	Purported Name of manufacturer	Remarks
1	**Influvac Tetra Vaccine**	P13	***Purported to be manufactured by:*** M/s Abbott Biologicals B.V., the Netherlands.	The suspected batch i.e. P13 is found to be Spurious/Falsified.

Risk Statement:

The use of above-mentioned Spurious/Falsified Vaccine i.e. Influvac Tetra Vacine (Batch # P13) may pose serious safety and quality concerns for Public Health as administration of a Spurious/Falsified vaccine may fail to provide the intended immunological protection and could expose recipients to unknown safety risks.

Action Initiated: -

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been asked to conduct surveillance activities throughout the supply chain to confiscate the Spurious/Falsified products.

DRAP, Islamabad + 92 051 9255969 gsms@dra.gov.pk

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

Advice for Consumers:

Consumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above-mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے علاج

DRAP, Islamabad
+ 92 051 9255969
gsms@dra.gov.pk